logo
Share SHARE
FONT-SIZE Plus   Neg

Immunomedics Reveals Study Results For Radioimmunotherapy Of Colorectal Cancer

Biopharmaceutical company Immunomedics Ic (IMMU: Quote) Monday revealed that colorectal cancer can be safely, specifically and rapidly targeted with TF2 bispecific antibody and a radiolabeled peptide, with limited toxicity to the patient.

The company stated that TF2 is a bi-specific antibody created using the patented Dock-and-Lock conjugation technology. In addition to targeting the carcinoembryonic antigen expressed by many human cancers, TF2 has been engineered to recognize a small peptide that carries radioactivity. This allows the injection of radioactivity to be separated from the administration of the tumor-targeting bispecific antibody, a concept known as pretargeting.

The company further stated that the study results revealed that pretargeting has the potential advantage of delivering increased radiation dose levels selectively to the tumors while minimizing the body's exposure to radiation's harmful side effects.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Social game developer Zynga Inc. said Wednesday after the markets closed that its first quarter loss narrowed from last year, as revenue increased and costs and expenses fell. The company's quarterly adjusted loss per share was also narrower than analysts estimated and its quarterly revenue beat analysts' forecast. Twenty-First Century Fox reported a better-than-expected third-quarter profit, on growth at its cable and film entertainment business, partly offset by the absence of Super Bowl as well as currency headwinds. Activision Blizzard Inc. (ATVI) on Wednesday reported a surge in profit for the first quarter, as revenues increased reflecting strong growth in digital business with the video game publisher's profit and revenues topping Wall Street estimates. Moving ahead, the company detailed a weak outlook for...
comments powered by Disqus
Follow RTT